Clinical Trial Update: Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) [Phase 2]

View source ↗

Summary

Phase 2 study of pembrolizumab as monotherapy in advanced hepatocellular carcinoma (MK-3475-224/KEYNOTE-224) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-04-04